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Individuals with glucocorticoid-induced osteoporosis experience vertebral fractures at an increased rate and at higher vertebral
areal bone mineral density (aBMD) than individuals with primary osteoporosis. Standard posteroanterior- (PA-) projection dual
energy X-ray absorptiometry (DXA) lacks the diagnostic sensitivity required for reliable estimation of vertebral fracture risk in
individuals. Assessment of subregional vertebral aBMD using lateral-projection DXA may improve the predictive value of DXA
parameters for fracture. One hundred and four individuals were recruited and grouped for this study: primary osteoporosis with
no history of vertebral fracture (𝑛 = 43), glucocorticoid-induced bone loss (𝑛 = 13), and healthy controls (𝑛 = 48). Standard
PA-projection and supine-lateral scans were performed, and lateral scans were analysed according to an established protocol to
measure aBMD within 6 subregions. Main effects for subregion and group were assessed and observed, by ANCOVA. Ratios were
calculated between subregions and compared between groups, to overcome the potentially confounding influence of variability in
subregional geometry. Significantly lower values were observed in the glucocorticoid group for the ratios of (i) anterior subregion:
whole vertebral body and (ii) posterior: whole vertebral body when compared to the primary osteoporosis and control groups
(𝑃 < 0.05). Lower anterior subregional aBMD in individuals on glucocorticoid therapy may help to explain the increased vertebral
fracture risk in this patient group.
1. Introduction
Glucocorticoid therapy is widely used for the management
of inflammatory and allergic conditions. While being effec-
tive in ameliorating these conditions, glucocorticoids can
adversely affect bone quality and bone strength [1], thereby
leading to an increased propensity to fracture. Secondary
bone fragility or osteoporosis due to glucocorticoid therapy,
termed glucocorticoid-induced osteoporosis (GIO), is a clin-
ically important phenomenon. This is primarily because of
reduced skeletal integrity predisposing to fragility fracture,
but also because patients with GIO experience vertebral
fractures at a rate which exceeds individuals with primary
osteoporosis, despite a comparable areal BMD (aBMD) [2–7].
Identifying possible mechanisms underlying this observation
is therefore important.
The effects of glucocorticoids are mediated by the cytoso-
lic glucocorticoid receptor [8] (cGCR), which is expressed on
a variety of skeletal and extraskeletal cells [9]. The adverse
effects of glucocorticoids on bone are complex and are both
direct and indirect. Important direct effects include an early
transient increase in osteoclastic bone resorption, a reduction
in osteoblast differentiation and function, and an increase in
osteocyte apoptosis [10]. There may also be indirect effects
leading to increased fracture risk including glucocorticoid-
induced myopathy [11].
This may explain the rapid early phase of bone loss upon
commencement of therapy. Glucocorticoids similarly affect
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bone loss due to their proapoptotic effects on osteoblasts and
osteocytes [8, 12, 13]. Defects in the osteocyte network within
bone negatively affect bone mineralisation and microarchi-
tecture and may explain the exaggerated trabecular bone loss
[3, 7, 14].
Vertebral fractures are the most common type of
osteoporosis-related fracture [15–17] and often present with-
out obvious acute symptoms [18], leading to lack of recog-
nition and treatment. Vertebral fractures frequently occur
spontaneously or from minor trauma [18] and are associated
with morbidity including decreased physical function (e.g.,
balance and muscle function), loss of height, compromised
pulmonary capacity, increased thoracic kyphosis, and acute
and chronic back pain [6, 15, 17–21]. These sequelae become
more significant with increasing numbers of vertebral frac-
tures. Vertebral fractures strongly predict the risk of future
fracture [22–25], in particular subsequent vertebral and, to a
lesser extent, appendicular fractures.
Possible explanations for the increased vertebral fracture
risk among individuals with GIO compared to those with
primary osteoporosis may lie in the pathophysiology of bone
loss with underlying systemic inflammatory disease in these
individuals, in particular rheumatoid arthritis, which has
been found to be associated with increased fracture risk
[26, 27], the pharmacokinetics of glucocorticoids, or perhaps
poor measurement specificity of bone parameters like aBMD
in these individuals.
Posteroanterior- (PA-) projection dual energy X-ray
absorptiometry (DXA) is the most commonly used modality
for the measurement of aBMD at the hip and lumbar spine
[28]. A strong relationship exists between aBMD and bone
mineral content (BMC) derived from PA-projection DXA
scans [29] and these variables are used ubiquitously to diag-
nose and monitor skeletal integrity. However, they cannot be
used to reliably predict an individual’s vertebral fracture risk,
particularly in the context of glucocorticoid-induced bone
loss [30–32]. Lateral-projection DXA has better specificity
and sensitivity when detecting vertebral osteoporosis and
age-related bone loss and is better able to detect vertebral
fractures than PA-projection scanning [30, 32–35]. These
attributes of lateral-projection scanning are most likely
related to the ability to isolate the vertebral body from the
cortical bone-rich posterior elements of the vertebra, thus
limiting the analysis to the metabolically-active trabecular
bone of interest.
Lateral-projection scans also enable measurement of
BMC and aBMD in intravertebral subregions. Variation in
aBMD between intravertebral subregions could explain why
one individualmay sustain a vertebral fracture whilst another
may not, due to subregional variation in bone compressive
strength; in essence, a chain is only as strong as its weakest
link. Ex vivo research undertaken by Wegrzyn et al. [36]
supported this hypothesis and suggested that trabecular
microarchitecture and its associated regional heterogeneity
contribute to vertebral fracture risk prediction. Older studies
utilising histomorphometry, QCT, and DXA techniques have
consistently shown relatively lower bone volume and trabecu-
lar thickness in both central and anterior vertebral subregions
[36–40]. These ex vivo studies suggest that there could be a
difference in intravertebral aBMD between individuals with
and without vertebral fracture and potentially in those with
glucocorticoid-induced bone loss.
A technique to measure in vivo vertebral subregional
aBMD has been developed by our research team with a
matched supine-lateral DXA scanning technique using a
Hologic QDR4500A densitometer [41]. Subsequent studies
have further validated the subregional methodology, estab-
lishing high short-term in vivo precision [41], moderate to
high intrarater and interrater precision [41], and concurrent
validity when compared with pQCT and micro-CT [42].
Validation findings were later replicated using a much larger
sample size [43], demonstrating that lateral DXA is valid
when measuring heterogeneity in aBMD between intraverte-
bral subregions. Lateral DXAmeasurement of aBMDhas also
been shown to be a better predictor of vertebral failure load
at both the whole vertebral body [44] and within subregions
[45], compared with standard PA DXA.
BMC derived from DXA is directly influenced by bone
size; thus, comparing BMC between large and small stature
people becomes problematic. While normalising BMC to
projection area, creating aBMD (g/cm2), corrects somewhat
for variability in bone size, aBMD is still influenced by bone
size as it cannot account for bone depth and thus cannot
measure true (volumetric) bone density, which remains
independent of bone size. Consequently, comparing subre-
gional aBMD (srBMD) between individuals is not valid, due
to inevitable heterogeneity in subregional bone geometry
among individuals. To minimise the potentially confounding
effect of variable subregional bone geometry on srBMD
differences, ratios of srBMDmay be compared between indi-
viduals. Deriving a ratio index of srBMD from an individual
and comparing it to the same ratio in other individuals
eliminate the potentially confounding effect of differences
in subregional geometry between individuals. Therefore, the
aim of this study was to compare srBMD ratios between indi-
viduals with primary and secondary osteoporosis as a means
to explain a possible mechanism underlying the increased
rate of vertebral fractures observed in GIO populations.
2. Materials and Methods
2.1. Design. Across-sectional cohort studywas undertaken in
a tertiary hospital-based bone densitometry unit (BDU).
2.2. Participants. A convenience sample of 104 individuals
was recruited sequentially for this study to form three
participant groups. These were (i) individuals diagnosed
with primary osteoporosis who had no history of vertebral
fracture (𝑛 = 43), (ii) individuals diagnosed with glucocorti-
coid-induced osteoporosis (GIO) or glucocorticoid-induced
osteopenia who had no history of vertebral fracture (𝑛 = 13),
and (iii) healthy controls (𝑛 = 48). Participants in the GIO
and primary osteoporosis groups were referred to the BDU
for clinical scanning purposes, while control participants
were recruited from the community through advertisements
in local media. The study protocol was approved by the
Human Research Ethics Committee of Melbourne Health
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(2009.085). All participants provided written, informed con-
sent to participate.
General inclusion criteria were that all participants were
required to be aged ≥50 years old; female participants had to
have been at least 5-year postmenopausal, defined as 5 years
or more, since their last menstrual period; and all individ-
uals were required to be independent with ambulation and
activities of daily living. General exclusion criteria included
a history of spinal surgery, any vertebral fracture classified
as Grade 1 or higher according to the Genant criteria [46], a
body mass index (BMI) greater than 33 or less than 18 kg/m2,
any formally diagnosed musculoskeletal conditions in the
spine that may affect the accuracy of a spinal DXA scan, and
the current use of bone-active therapies. To be included in
the glucocorticoid group, participants needed to have had a
history of glucocorticoid use of ≥5mg/day of prednisolone
continuously for at least 6monthswithin the last 3 years along
with the diagnosis of either osteoporosis or osteopenia, based
on WHO criteria, using DXA-derived T-scores (T-score ≤
−1.5) from either the total hip, total spine, or L3 vertebral
body. Individuals in the primary osteoporosis group were
required to have a diagnosis of osteoporosis based on WHO
criteria (T-score ≤ −2.5) at the total hip, total spine, or L3
vertebral body from the PA-projectionDXA scan. Individuals
in the control group were required to have normal BMD
based on WHO criteria (T-score > −1.0) at all of these sites.
Eligibility to participate was determined from a telephone
interview and a review of DXA data from formal clinical
scans (GIO and primary osteoporosis groups) or voluntary
research scans (control group).
2.3. Protocol. Each participant attended the BDU where
demographic and clinical data were collected via question-
naire and height (cm) and mass (kg) measured to ensure
their BMI fell within the required range of 18–33 kg/m2. After
DXA scanning, a 10-year risk of sustaining a hip or major
osteoporotic fracture was calculated using the FRAX tool
using Australian reference data [47].
2.4. Bone Densitometry
2.4.1. DXA Scanning. All participants were scanned on a
Hologic QDR4500A fan beam densitometer (Bedford, MA,
USA), using Hologic software version 9.10D. To monitor the
reproducibility of themachine’s results, a quality control spine
phantom with known BMC was scanned daily prior to any
patient scans. Over the data collection period, the mean
coefficient of variation (%CV)was 0.35%, indicating excellent
temporal stability of the machine.
All participants underwent standard PA-projection scan-
ning of the hip and spine, following standard Hologic
protocols to derive aBMD, BMC, T-scores, and Z-scores at
the right hip and spine, either for clinical (GIO and primary
osteoporosis groups) or research (control group) purposes.
These standard scans were used to determine group eligi-
bility according to WHO classification criteria. In order to
exclude the presence of vertebral fracture, Instant Vertebral
Assessment (IVA) scans were acquired to assess vertebral
morphometry between T5 and L4 (Hologic software 9.10D).
IVA has been reported to have high specificity (>90%),
high sensitivity (70–86%), negative predictive values (93.6–
99.4%), and good reliability between raters [16, 17, 25, 48, 49].
A matched supine-lateral scan of the lumbar spine was then
acquired using the array scanningmode and this scan set was
used for measurement of srBMD.
2.4.2. DXA Analysis. Standard PA DXA scans of the hip
and spine were analysed according to the manufacturer’s
instructions [50]. A combination of qualitative and quanti-
tative methods was used to identify and diagnose vertebral
fracture(s) on the basis of images gained from IVA scanning.
Vertebral fractures were defined as grade 2 deformity or
higher according to the semiquantitative method described
by Genant et al. [46]; a method with excellent reproducibility
[51, 52]. This was achieved by visual inspection of vertebral
morphometry, from the IVA scan, and a measured reduction
in anterior,middle, or posterior vertebral height of at least 25–
40% or a 20–40% reduction in vertebral area, as calculated by
Hologic software 9.10D. Adjustment factors calculated from
normal vertebral height ratios, established by Diacinti et al.
[53] for T5-L4, were included in the calculation of height
ratios, serving as reference data to limit overestimation of
fracture incidence. The reliability of IVA scans to diagnose
vertebral fractures has been established previously by Cha-
purlat et al. [49].
Lumbar spine images acquired from the lateral DXA
scanswere used to calculate aBMD in seven regions of interest
(ROIs) at the L3 vertebral body (Figure 1), consistent with
established protocols for which reliability and validity have
been established [38, 41–45, 54]. L3 was used as the target
vertebra as it is less affected by overlapping ribs than L2 [55].
Prior to the subregional ROI analysis, the global ROI window
used during the Hologic analysis was set with a maximum
height of 151 pixels andwidth of 141 pixels to ensure consistent
software-defined analysis parameters between images. ROI
1 was defined as the entire vertebral body area and hence
was demarcated by the four borders of the L3 vertebral
body (superior and inferior endplates and anterior/posterior
edges of the centrum). ROI 1 was therefore comparable to
the vertebral area used to calculate aBMD in the standard
Hologic analysis of lateral scan data. ROIs 2–7 consisted of
six intravertebral subregions, of which the size and shape
were selected manually. ROIs 2–4 were sagittally orientated,
equally dividing ROI 1, by width, into thirds. ROIs 5–7 were
oriented transversely, again dividing the total area of ROI
1 into equal thirds, by height. A consistent pixel width and
height for sagittal and transverse subregions were employed
to maintain the uniformity of dimensions. After the size
and shape of the subregions were defined, individual aBMD
measurements were calculated for each ROI.
2.5. Data Analysis. Descriptive and clinical characteristics
were compared between the three groups using a one-
way ANOVA. Differences in srBMD between groups were
examined with two 3 × 4 ANCOVAs with one repeated
measure. For each model, “group” was set as the between-
subject factor (𝑘 = 3) and ROI as the within-subject repeated
measure (𝑘 = 4) a priori, while L3 vertebral body area (ROI 1
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Region 1: whole area (integrated
cortical and trabecular bone) of the
vertebral body, defined by the four
corners of the vertebral body in the
sagittal plane
Subregion 2: posterior third of ROI 1
Subregion 3: middle third of ROI 1
Subregion 4: anterior third of ROI 1
Subregion 5: superior third of ROI 1
Subregion 6: central third of ROI 1






Figure 1: DXA-derived vertebral subregions defined using Hologic
software. ROI 1 (whole) was defined by the four corners of the
vertebra. ROIs 2–4 (posterior, middle, and anterior) formed equal
thirds in the area of ROI 1, oriented sagittally. ROIs 5–7 (superior,
central, and inferior) formed equal thirds in area of ROI 1, oriented
transversely. Reprinted from Briggs et al. [42] with permission from
Elsevier Copyright Clearance Center.
area), derived from the lateral-projection scan, was used as
a covariate to account for observed variability in bone size
between the groups. To ensure that no overlapping subregions
were compared post hoc, ANCOVA 1 included whole verte-
bral area (ROI 1) and the three subregions orientated sagittally
(ROIs 2–4), whilst ANCOVA 2 included ROI 1 and the three
subregions orientated transversely (ROIs 5–7).
To minimise the potentially confounding influence of
subregional geometry on subregional BMD values between
groups, ratios of srBMDwere compared between groups with
a one-way ANOVA. Twelve ratios were derived: six com-
paring subregional values (ROIs 2–7) to the whole vertebral
area (ROI 1) and six comparing non-overlapping subregions,
consistent with an earlier analysis [54].
The critical alpha level of significance was set at 0.05 (2-
tailed) and Bonferroni corrections were made for multiple
post hoc comparisons in all statistical models. Statistical anal-
ysis was undertaken using SPSS version 19.1 for Windows.
3. Results
3.1. Descriptive Measures. While there was no difference in
age and height between the groups, there was a significantly
greater proportion of males in the GIO group compared
to the other groups (Table 1). Significant differences were
also observed between the groups for mass, BMI, FRAX
score, T-scores for the spine and hip, and L3 vertebral body
area (ROI 1). The GIO group had significantly higher mass
(mean difference (MD) = 13.77 kg, 95% CI = 4.96–22.58),
BMI (MD = 3.00 kg/m2, 95% CI = 0.48–5.53), T-scores at
the PA total spine (MD = 0.99 SD, 95% CI = 0.16–1.82) and
the total hip (MD = 0.69 SD, 95% CI = 0.06–1.32), and a
significantly larger L3 vertebral body area (MD = 2.27 cm2,
95% CI = 0.46–4.07) compared to the primary osteoporosis
group.When compared to controls, the primary osteoporosis
group was observed to have significantly lower mass (MD =
10.06 kg, 95% CI = 4.33–15.91), lower BMI (MD = 2.65, 95%
CI = 0.97–4.33) and lower T-scores at the PA total spine
(MD = 2.66, 95% CI = 2.11–3.21), lateral spine (MD = 1.40,
95% CI = 0.73–2.06), and total hip (MD = 1.86, 95% CI =
1.44–2.28). The GIO group also had significantly lower T-
scores at the PA total spine (MD = 1.67, 95% CI = 0.85–2.48)
and significantly higher FRAX hip scores (MD = 1.67, 95%
CI = 0.42–2.43) compared to controls. Both the GIO and
primary osteoporosis groups had significantly higher FRAX
major osteoporotic fracture scores than controls (MD = 3.42,
95%CI= 0.89–5.95 andMD= 1.96, 95%CI= 0.13–2.80, resp.).
3.2. Differences in Mean Areal srBMD between Groups
3.2.1. Sagittal Subregions. A main effect for subregion was
observed (𝐹 = 4.29, 𝑃 < 0.01), with mean adjusted
aBMD in all subregions being significantly different from
each other (𝑃 < 0.0001). All analyses were adjusted for ROI
1 area, to account for differences in vertebral size between
groups. One exception was observed for the whole vertebral
body (ROI 1) mean adjusted aBMD versus middle subre-
gional (ROI 3) mean adjusted aBMD (𝑃 = 1.00). The lowest
adjusted mean (±SD) aBMD was observed in the anterior
subregion (0.411 ± 0.126 g/cm2) (ROI 4) and the highest
in the posterior subregion (0.583 ± 0.137 g/cm2) (ROI 2),
and importantly, these adjusted mean srBMD values varied
significantly from the adjusted mean srBMD of the whole
vertebral body (Figure 2). Amain effect for group (𝐹 = 15.75,
𝑃 < 0.0001) was observed, reflecting lower adjusted mean
srBMD in both the GIO and primary osteoporosis groups
compared to controls (MD = 0.14 g/cm2, 95% CI = 0.05–0.24
and MD = 0.12 g/cm2, 95% CI = 0.05–0.18, resp.) (Figure 2).
No significant difference was observed between the GIO and
primary osteoporosis groups.
No significant group × subregion interaction main effect
was observed (𝐹 = 1.44, 𝑃 = 0.169); however, adjusted
mean (±SD) aBMD in the anterior subregion (ROI 4) was
lower in the GIO group (0.355 ± 0.148 g/cm2) compared to
the primary osteoporosis group (0.416 ± 0.079 g/cm2, MD =
0.06 g/cm2, 95% CI = 0.031–0.09) (𝑃 = 0.017), a result not
observed at any other subregion. This finding represented an
effect size (Cohen’s 𝑑) of 𝑑 = 0.51.
3.2.2. Transverse Subregions. Amain effect for subregion was
observed (𝐹 = 2.80, 𝑃 = 0.04), with mean adjusted aBMD
in all subregions being significantly different from each other
(𝑃 < 0.0001), with the exception of the whole vertebral
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Table 1: Descriptive measures for each group and pooled data, expressed as the mean (SD) for age, height, mass, and BMI and as the mean
(95% CI) for FRAX data, 𝑇-scores, and L3 area.
Descriptive measure Group Pooled
Primary osteoporosis GIO Control
𝑁 (% female) 43 (95.3) 13 (30.8) 48 (83.3) 104 (81.7)
Age (years) 61.1 (5.0) 63.7 (7.8) 61.5 (5.6) 62.1 (6.1)
Height (cm) 163.1 (7.6) 169.1 (8.7) 166.8 (6.5) 166.3 (7.6)
Mass (kg) 61.8 (10.0)b,c 75.6 (16.1)a 71.9 (8.8) 69.8 (11.6)
BMI (kg/m2) 23.2 (3.0)b,c 26.2 (3.7)a 25.8 (2.8) 25.1 (3.2)
FRAX major osteoporotic (%) 4.5 (3.7 to 5.4)c 6.0 (3.3 to 8.7)c 2.6 (2.0 to 3.2) 4.4 (3.0 to 5.8)
FRAX hip (%) 1.1 (0.8 to 1.4) 2.1 (0.8 to 3.4)c 0.4 (0.1 to 0.7) 1.2 (0.6 to 1.8)
𝑇-score PA spine (L1–4) −2.6 (−2.9 to −2.4)b,c −1.6 (−2.4 to −0.9)a,c 0.0 (−0.2 to 0.3) −1.4 (−1.8 to −1.0)
𝑇-score total hip −2.0 (−2.2 to −1.8)b,c −1.3 (−1.9 to −0.8)a,c −0.2 (−0.4 to 0.1) −1.8 (−1.5 to −0.8)
L3 area (ROI 1) (cm2) 8.8 (8.1 to 9.5)b 11.1 (10.1 to 12.0)a 9.9 (9.1 to 10.0) 9.9 (9.1 to 10.5)
aSignificant difference compared to the primary osteoporosis group (𝑃 < 0.01); bsignificant difference compared to the GIO group (𝑃 < 0.01); csignificant
difference compared to control group (𝑃 < 0.01).

































Figure 2: ANOVA 1, mean areal BMD for sagittal regions of interest
between groups, adjusted for ROI 1 area. Error bars are SEM. ∗Sig-
nificantly different to controls (𝑃 < 0.0001). #Significantly different
compared to all other ROIs. ∧Significantly different to ROIs 2 and 4.
body (ROI 1) adjusted mean aBMD versus superior sub-
regional (ROI 5) adjusted mean aBMD (𝑃 = 1.00). The
lowest adjusted aBMDwas observed in the central subregion
(0.451 ± 0.133 g/cm2) (ROI 6) and the highest in the inferior
subregion (0.559 ± 0.122 g/cm2) (ROI 7), and importantly,
these adjusted mean srBMD varied significantly from the
adjustedmean srBMDof the whole vertebral body (Figure 3).
A significant main effect for group (𝐹 = 15.96, 𝑃 < 0.0001)
was observed, with lower adjusted mean srBMD in both the
primary osteoporosis and GIO groups compared to controls
(MD=0.108 g/cm2, 95%CI = 0.05–0.17 andMD=0.14 g/cm2,


































Figure 3: ANOVA 2, mean areal BMD for transverse regions of
interest between groups, adjusted for ROI 1 area. Error bars are SEM.
∗Significantly different to controls (𝑃 < 0.0001). #Significantly dif-
ferent compared to all other ROIs. ∧Significantly different to ROIs 6
and 7.
95% CI = 0.06–0.23, resp.) (Figure 3). No significant group ×
subregion interaction was observed (𝑃 = 0.88).
3.3. Ratios of srBMD. Table 2 displays srBMD ratio compar-
isons between groups. Comparing subregions to the whole
vertebral area, the GIO group demonstrated a significantly
higher ratio for ROI 2 : ROI 1 (1.27) when compared with
the primary osteoporosis (1.13; MD = 0.13, 95% CI = 0.04–
0.23) and control groups (1.16; MD = 0.12, 95% CI = 0.01–
0.20) (𝑃 < 0.05) and a significantly lower ratio for ROI
4 : ROI 1 (0.72) when compared to the primary osteoporosis
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Table 2: Mean (95% CI) ratio values of srBMD for all groups.
Ratio for subregions Primary osteoporosis GIO Control
Posterior : whole (2 : 1) 1.13 (1.09–1.17) 1.27 (1.15–1.38)a 1.16 (1.12–1.19)
Middle : whole (3 : 1) 1.01 (0.99–1.03) 1.01 (0.92–1.10) 1.00 (0.98–1.01)
Anterior : whole (4 : 1) 0.84 (0.81–0.88) 0.72 (0.58–0.86)a 0.83 (0.80–0.86)
Superior : whole (5 : 1) 0.95 (0.93–0.98) 1.01 (0.94–1.10) 1.00 (0.96–1.04)
Central : whole (6 : 1) 0.90 (0.87–0.92) 0.85 (0.78–0.92) 0.92 (0.89–0.95)
Inferior : whole (7 : 1) 1.14 (1.12–1.18) 1.13 (1.02–1.24) 1.08 (1.05–1.11)
Middle : posterior (3 : 2) 0.90 (0.86–0.95) 0.81 (0.71–0.91) 0.87 (0.84–0.90)
Anterior : posterior (4 : 2) 0.76 (0.70–0.82) 0.59 (0.45–0.74)a 0.73 (0.69–0.77)
Anterior :middle (4 : 3) 0.84 (0.80–0.88) 0.75 (0.56–0.93) 0.84 (0.80–0.88)
Central : superior (6 : 5) 0.95 (0.91–1.00) 0.85 (0.75–0.95) 0.94 (0.89–0.99)
Superior : inferior (5 : 7) 0.85 (0.80–0.90) 0.93 (0.77–1.09) 0.95 (0.88–1.01)
Central : inferior (6 : 7) 0.80 (0.76–0.84) 0.78 (0.65–0.91) 0.86 (0.81–0.92)
aSignificant difference compared to both primary osteoporosis and control groups (𝑃 < 0.05).
(0.84; MD = 0.13, 95% CI = 0.02–0.23) and control (0.83;
MD = 0.12, 95% CI = 0.01–0.22) groups (𝑃 < 0.05). Com-
paring between subregions, the GIO group demonstrated a
significantly lower ratio for ROI 4 : ROI 2 (0.59), compared
to the primary osteoporosis (0.76; MD = 0.17, 95% CI = 0.03–
0.31) and control (0.73; MD = 0.14, 95% CI = 0.00–0.27)
groups (𝑃 < 0.05). No significant differences in srBMD
ratios were observed between the primary osteoporosis and
control groups for any ratio.
4. Discussion
4.1. Main Finding. Primarily, this study has shown that DXA
can identify differences in srBMD within a vertebra, as
displayed by the significant main effect for subregion (𝑃 <
0.05), consistent with earlier data [38, 42, 43]. Secondly, it was
found that the GIO group demonstrated significantly lower
results for the anterior subregion : whole vertebra ratio (ROI
4 : ROI 1) and the anterior subregion : posterior subregion
ratio (ROI 4 : ROI 2) when compared to both the primary
osteoporosis and control groups.These datamay help explain
why vertebral fractures occur at relatively higher PA aBMD
values thanwhat is seen in typical primary osteoporosis, since
the intravertebral distribution of bone appears to be abnor-
mal in glucocorticoid-treated patients but not in patients with
primary osteoporosis. The findings indicate that the anterior
subregion may be of particular interest in a GIO population
for assessing individuals’ risk of vertebral fracture and that
the ratio technique may prove useful in a clinical setting as a
means of determining bone distribution without needing to
adjust for vertebral size.
4.2. Sagittal Subregional Intravertebral aBMD Profile (ROIs 2–
4). Main effects for both subregion and groupwere observed,
demonstrating that this study, along with the earlier pilot
work [56], has been able to show differences in subregional
aBMD in vivo. The lowest mean srBMD was observed in the
anterior subregion (ROI 4), a result consistent with previous
ex vivo histomorphometry, QCT, and DXA studies [36–40,
42, 43] and the highestwas in the posterior subregion (ROI 2).
This distribution pattern is probably explained by a combi-
nation of a higher cortical bone component in the posterior
subregion compared to the anterior subregion and a result of
changes in vertebral loading profiles, in particular interver-
tebral disc degeneration and changes in lumbar spine pos-
ture [21, 57]. When disc degeneration occurs, force loading
increases on the neural arch, hence decreasing loading on the
anterior region and causing regional demineralisation [57–
59]. Although no significant group × subregion interaction
effect was observed, we detected significantly lower srBMD in
the anterior subregion (ROI 4) for the GIO group compared
to the primary osteoporosis group. Despite a significant
finding with a medium effect size, this result should be
considered in the context of a relatively small sample size and
disproportionate sex distribution. Nonetheless, this result
occurred despite the larger proportion of male patients in the
GIO group which intuitively would have increased the mean
aBMD in the GIO group, relative to a female-dominated
GIO group. If all confounding factors were removed and
sample sizes increased and balanced between the groups,
this difference in aBMD may have been even more marked.
We observed a power of 44% for this two-tailed analysis,
suggesting that with a larger sample size, in the order of 60
per group, a power of 80% could be achieved.
4.3. Transverse Subregional Intravertebral aBMDProfile (ROIs
5–7). As with the sagittal subregions, main effects were
observed for both subregion and group.The central subregion
(ROI 6) exhibited the lowest aBMD, a result consistent with
previous ex vivo studies [36–40, 42, 43].The highest observed
aBMD was in the inferior subregion (ROI 7) and may be
explained due to this region’s proximity to the chondral
endplate, an area rich in cortical bone [60]. There was no
significant subregion × group interaction observed nor were
there any significant differences in supero-inferior ratios.This
was not consistent with previous findings suggesting lower
bone content at the central subregion.
4.4. Ratios. While it is possible to compare srBMD between
groups, caution is required due to variability in subregional
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bone geometry. The comparison of ratios is therefore a
feasible approach to account for differences in vertebral size
and may reduce gender effects caused by differences in bone
size. Ratios also provide information on the distribution
of bone within the subregions; hence the lower observed
ROI 4 : ROI 2 and ROI 4 : ROI 1 ratios suggest less bone is
distributed into the anterior subregion compared to the
posterior subregion and vertebral body as a whole. This may
suggest that the anterior subregion is at an increased risk of
fracture (particularly anteriorwedge fracture)within individ-
uals exposed to glucocorticoid therapies, compared to other
subregions, whilst the posterior subregion appears to be less
affected.
4.5. Strengths and Limitations. Strengths of this study include
the use of the widely employed Genant semiquantitative
approach [46] along with vertebral height reference data [53]
for fracture diagnosis and the use of our group’s established,
reliable, and validated subregional analysis protocol [41–43,
45, 54]. The relatively small sample in the GIO group led
to a sex imbalance between groups. Despite the GIO group
being predominantly male compared to the other groups
which were predominantly female, statistically and clinically-
significant deficits were found in the glucocorticoid group.
Nonetheless, we cannot exclude the possibility that differ-
ences in intravertebral bone distribution were related to sex
differences between groups.The use of a cross-sectional study
design does not allow conclusions about causal relationships
and thus future longitudinal work would be beneficial in
strengthening this study’s findings.
4.6. Future Directions. The use of intravertebral aBMD
ratios to indicate abnormalities in bone distribution has the
potential for application in a clinical setting, especially for
men, where limited lateral reference data are available. The
subregional approach may enhance the ability to monitor
the effects of bone-active medications on bone architecture.
Intervention studies would lend further support to this
application of the technique.
5. Conclusions
A robust connection exists between aBMD and vertebral
strength, hence indicating the important role of BMD in
reflecting fracture risk. This study has shown that a lat-
eral subregional approach to aBMD measurement provides
greater information than standard PA-projection DXA about
differences in aBMD between individuals with GIO and
individuals with primary osteoporosis. In particular, gluco-
corticoid-treated patients had abnormal intravertebral dis-
tribution of bone, with relatively low aBMD in the anterior
subregion. Glucocorticoid-treated individuals at high risk of
sustaining vertebral fractures may be better identified with
the clinical application of this technique.
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